COMMUNIQUÉS West-GlobeNewswire
-
Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026
16/10/2025 -
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
16/10/2025 -
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
16/10/2025 -
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
16/10/2025 -
RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting
16/10/2025 -
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
16/10/2025 -
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
16/10/2025 -
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
16/10/2025 -
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
16/10/2025 -
Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire
16/10/2025 -
AVITA Medical Announces CEO Transition
17/10/2025 -
Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)
16/10/2025 -
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
16/10/2025 -
Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
16/10/2025 -
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
16/10/2025 -
AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute
16/10/2025 -
Wounded Warriors Family Support Donates 2025 Ford F-150 Truck to Retired Marines Veteran
16/10/2025 -
Celebrating 50 Years of Katena: From One Woman’s Vision to a Global Legacy in Ophthalmology
16/10/2025 -
EssilorLuxottica: Q3/9M 2025 Revenue - Revenue up 11.7% in the third quarter, best quarterly performance ever for the Group
16/10/2025
Pages